Advancing APP-Led Care in Frontline Metastatic Triple-Negative Breast Cancer

Chapter 1: The Evolving Frontline mTNBC Landscape

This chapter establishes the current clinical context for metastatic triple-negative breast cancer, highlighting the disease burden, persistent unmet needs, and recent guideline shifts in the frontline setting. Faculty discuss why these updates matter for advanced practice providers (APPs), particularly in community practices where APPs often serve as a primary point of contact for patient education, treatment coordination, and care continuity. 

Chapter 2: ADCs in the Frontline mTNBC Setting This chapter reviews the evolving evidence base supporting antibody-drug conjugate (ADC) approaches in frontline metastatic triple-negative breast cancer, with a focus on pivotal Phase III trial data and the rationale for Trop-2–directed therapies. Faculty explore efficacy, safety, and key mechanistic differences across ADCs, helping advanced practice providers understand how emerging data may inform treatment conversations and clinical decision-making. 

Chapter 3: The APP's Role in AE Management and Patient Support 

This chapter focuses on the essential role of advanced practice providers in anticipating, monitoring, and managing adverse events associated with Trop-2–directed antibody-drug conjugates. Faculty provide practical strategies for patient education, diarrhea and neutropenia management, proactive monitoring, and supportive care—especially for patients treated in community settings. 

Chapter 4: Bringing mTNBC Guidelines to the Bedside 

This chapter translates frontline metastatic triple-negative breast cancer guideline updates into real-world practice. Using a patient case vignette, faculty discuss treatment sequencing, patient counseling, logistical barriers, and the infrastructure needed to deliver newer regimens effectively in community oncology settings.